What is the recommended rabies post‑exposure prophylaxis regimen using monoclonal antibody?

Rabies Post-Exposure Prophylaxis with Monoclonal Antibodies

For previously unvaccinated patients with WHO Category III rabies exposure, administer rabies monoclonal antibody (RmAb) at 0.3 mg/kg (or 3.33 IU/kg) infiltrated into and around the wound on day 0, combined with rabies vaccine given intramuscularly on days 0,3,7, and 14.

Core Regimen Components

The complete post-exposure prophylaxis regimen consists of three essential elements:

1. Immediate Wound Care

• Thoroughly cleanse all wounds with soap and water immediately
• Use a virucidal agent (povidone-iodine solution) to irrigate wounds if available 1

2. Passive Immunization with Monoclonal Antibody

Dosing and Administration:

• Dose: 0.3 mg/kg body weight (equivalent to approximately 3.33 IU/kg) 2, 3
• Timing: Administer on day 0 only
• Route: Infiltrate the full dose into and around the wound(s) if anatomically feasible
• Any remaining volume: Inject intramuscularly at a site distant from vaccine administration
• Critical: Do NOT administer in the same syringe or same anatomic site as the first vaccine dose 1

3. Active Immunization with Vaccine

Standard 4-dose regimen for immunocompetent patients:

• HDCV or PCECV: 1.0 mL intramuscularly on days 0,3,7, and 14 1
• Site: Deltoid area for adults and older children; anterolateral thigh for younger children
• Never use gluteal area (diminished immunologic response) 1

Modified 5-dose regimen for immunocompromised patients:

• Days 0,3,7,14, and 28 1

Evidence Supporting Monoclonal Antibodies

The recent high-quality evidence demonstrates that rabies monoclonal antibodies are superior to traditional immunoglobulin products:

Superior Early Protection:

• A 2025 phase 4 trial with 4,059 patients showed RmAb plus vaccine was safe and well-tolerated with no rabies cases during 1-year follow-up 2
• A 2025 phase 3 trial demonstrated Day 8 RVNA geometric mean was 4.34 IU/mL with SYN023 versus 0.23 IU/mL with HRIG (ratio 18.7, indicating marked superiority) 3
• 99.4% of monoclonal antibody recipients achieved protective RVNA levels by Day 4 versus only 4.5% with HRIG 4

Safety Profile:

• Fewer local injection site reactions compared to HRIG (22.0% vs 38.8%) 3
• Most adverse events are mild and transient 2
• No treatment-related serious adverse events in large trials 2

Critical Timing Considerations

Window for Passive Immunization:

• Ideally administer monoclonal antibody on day 0 with first vaccine dose
• If not given on day 0, can still administer up to and including day 7 of the vaccine series 1
• After day 7: Do NOT give passive immunization as it may interfere with active antibody production

Previously Vaccinated Patients

Simplified regimen (no passive immunization needed):

• Wound cleansing only
• Vaccine: 1.0 mL IM on days 0 and 3 only
• Do NOT administer monoclonal antibody or any immunoglobulin 1

This applies to anyone with documented prior complete pre-exposure or post-exposure vaccination with cell-culture vaccines.

Key Advantages of Monoclonal Antibodies Over Traditional RIG

1. Immediate protection: Achieves protective RVNA levels within 4 days versus 14+ days with HRIG 4
2. No disease transmission risk: Recombinant product eliminates blood-borne pathogen concerns
3. Better tolerability: Fewer injection site reactions 3
4. Consistent potency: No batch-to-batch variability
5. Improved availability: Can be manufactured at scale, addressing global RIG shortages

Common Pitfalls to Avoid

• Never exceed the recommended dose of monoclonal antibody—excess passive antibody can suppress active vaccine response 1
• Never inject vaccine in the gluteal area—this results in inadequate immune response 1
• Never give passive immunization after day 7—interferes with vaccine-induced immunity
• Never give passive immunization to previously vaccinated patients—unnecessary and may blunt anamnestic response 1
• Do not delay treatment waiting for monoclonal antibody if unavailable—traditional HRIG (20 IU/kg) or ERIG (40 IU/kg) remain acceptable alternatives per ACIP guidelines 1

The evidence strongly supports monoclonal antibodies as the preferred passive immunization component of rabies PEP, offering superior early protection and better tolerability than traditional immunoglobulin products while maintaining excellent long-term efficacy.